Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current pharmacotherapies for obesity: A practical perspective.

Angela Golden1

  • 1NP from Home LLC Munds ParkArizona.

Journal of the American Association of Nurse Practitioners
|October 13, 2017
PubMed
Summary

Pharmacotherapies for obesity management can aid individuals who haven

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey.

Obesity pillars·2026
Same author

Obesity competency for nurse practitioners: A call to action.

Journal of the American Association of Nurse Practitioners·2026
Same author

Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach.

Obesity pillars·2026
Same author

Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.

Obesity (Silver Spring, Md.)·2026
Same author

Nutrition and physical activity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022.

Obesity pillars·2023
Same author

Obesity history, physical exam, laboratory, body composition, and energy expenditure: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.

Obesity pillars·2023

Area of Science:

  • Pharmacology
  • Endocrinology
  • Public Health

Background:

  • Obesity is a complex chronic disease requiring multifaceted management strategies.
  • Lifestyle modifications (diet and exercise) are foundational but often insufficient for sustained weight loss in many individuals.
  • Pharmacotherapy offers an additional tool for obesity management, particularly for those with comorbidities.

Purpose of the Study:

  • To provide a comprehensive review of currently available pharmacotherapies for obesity management.
  • To focus on obesity medications approved and utilized within the United States.
  • To guide clinicians in selecting appropriate pharmacologic agents based on individual patient profiles.

Main Methods:

  • A narrative review methodology was employed.
  • Literature searches were conducted to identify relevant studies and data.
  • The latest prescribing information available up to July 2017 was incorporated.

Main Results:

  • Several pharmacotherapies are approved for obesity management in the US.
  • Phentermine is available for short-term use.
  • Long-term options include orlistat, lorcaserin, phentermine-topiramate, naltrexone-bupropion, and liraglutide 3.0 mg.

Conclusions:

  • Obesity pharmacotherapies can be beneficial for individuals who have not achieved success with lifestyle changes alone.
  • Treatment selection should be individualized, considering factors like contraindications, comorbidities, patient preferences, and cost.
  • Understanding the unique advantages, disadvantages, and patient-specific factors of each medication is crucial for effective obesity pharmacotherapy.
Keywords:
Nurse practitionersobesitypharmacotherapyweight management

Related Experiment Videos